N1-Heterocyclic pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase

Bioorganic & Medicinal Chemistry Letters
2010.0

Abstract

A series of N1-heterocyclic pyrimidinediones were extensively evaluated as HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs). Inhibitor 1 is active against NNRTI-resistant viruses including RT mutant K103N. The co-crystal structure of inhibitor 1 with HIV-1 RT revealed that H-bonds are formed with K101 and K103. Efforts to improve the suboptimal pharmacokinetic profile of 1 resulted in the discovery of compound 13, which represents the lead compound in this series with improved pharmacokinetics and similar potency as inhibitor 1.

Knowledge Graph

Similar Paper

N1-Heterocyclic pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase
Bioorganic & Medicinal Chemistry Letters 2010.0
N1-Alkyl pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase
Bioorganic & Medicinal Chemistry Letters 2010.0
Synthesis and biological activity of new pyridone diaryl ether non-nucleoside inhibitors of HIV-1 reverse transcriptase
MedChemComm 2010.0
Rational Design of Potent Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase
Journal of Medicinal Chemistry 2012.0
Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase
Bioorganic & Medicinal Chemistry Letters 2008.0
Design of Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase with Improved Drug Resistance Properties. 1.
Journal of Medicinal Chemistry 2004.0
Discovery of piperidin-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-Benzyl derivatives with broad potency against resistant mutant viruses
Bioorganic & Medicinal Chemistry Letters 2010.0
Picomolar Inhibitors of HIV-1 Reverse Transcriptase: Design and Crystallography of Naphthyl Phenyl Ethers
ACS Medicinal Chemistry Letters 2014.0
2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 NNRTIs: Rational Design, Synthesis, Activity Evaluation, and Crystallographic Studies
Journal of Medicinal Chemistry 2021.0
Design and synthesis of a new series of modified CH-diarylpyrimidines as drug-resistant HIV non-nucleoside reverse transcriptase inhibitors
European Journal of Medicinal Chemistry 2014.0